Compare Walmart Stores Inc (WMT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Walmart Stores Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Walmart Stores Inc trades at $109.88 (market cap $892.90B), while State Street SPDR S&P Biotech ETF trades at $154.37. The key difference: Walmart Stores Inc pays a 0.88% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Walmart Stores Inc nearer its low. Which is the better fit depends on your goals.
| WMT | XBI | |
|---|---|---|
Market Cap | $892.90B | — |
Volume | 5,675,288 | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $134.20 | $164.28 |
52-Week Low | $95.67 | $85.16 |
Enterprise Value | $956.35B | — |
Dividend Yield | 0.88% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Walmart (WMT) trades at $114.24, down 0.62% today, with a neutral technical signal and strong fundamentals including consistent earnings beats and robust cash flow. Revenue reached $681.0B in 2025 (source: company filings, 2025), with net income margin improving to 3.13%. Recent news highlights AI innovation and delivery expansion, while analyst consensus remains bullish with a $142.10 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include competitive pressure from Amazon and margin volatility. Wall Street's strong buy rating (72.72% of analysts) supports upside potential, though investors should monitor execution against guidance.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Read more on WMT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
